Back

Sequential mosaic variants in KRAS and STAT5B associated with a mixed phenotype of two acquired errors of immunity

Forkgen, J.; Masle-Farquhar, E.; Fontaine, Y.; Russell, A.; Ji, S.; Peters, T. J.; Qiao, Z.; Geaghan, M.; Jackson, K. J.; Hammond, J. M.; Deveson, I. W.; David, C.; Lemberg, D. A.; Gupta, N.; Fuentes-Bolanos, N.; Mustjoki, S.; Hwa, V.; Tangye, S. G.; Gray, P. E.; Siggs, O. M.

2024-08-08 allergy and immunology
10.1101/2024.08.07.24311150
Show abstract

Mosaic genetic variation has been implicated in the pathogenesis of both malignant and non-malignant immunological disease. Here, we report a unique case of postnatal acquisition of a gain-of-function (GoF) KRAS variant, with an additional GoF STAT5B variant, in a woman with inflammatory bowel disease, splenomegaly, thrombocytopenia, bronchiectasis, monocytosis, and eosinophilia. Targeted amplicon sequencing revealed widespread distribution of both variants in key immune cell populations, and in historical blood and tissue samples, with the emergence of both variants coinciding with the time of clinical presentation. Short- and long-read single cell RNA sequencing of patient cells highlighted a unique population of monocytes, with a broad distribution of both variants, and dysregulated cytokine signaling pathways. Flow cytometry revealed dysregulated STAT signaling, and the presence of a distinct population of highly granular CD24+ cells. Taken together with the clinical presentation, these findings led to a diagnosis of combined RAS-associated autoimmune leukoproliferative disorder (RALD) and non-clonal STAT5B GoF disease. To our knowledge, this is the first reported combination of two distinct acquired errors of immunity causing a mixed clinical phenotype, and highlights the importance of considering acquired monogenic diseases within a broader genomic context.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
The Journal of Immunology
based on 19 papers
Top 0.1%
7.5%
2
Journal of Experimental Medicine
based on 10 papers
Top 0.1%
6.3%
3
Nature Immunology
based on 14 papers
Top 0.1%
6.3%
4
Journal of Clinical Immunology
based on 11 papers
Top 0.1%
6.3%
5
Allergy
based on 13 papers
Top 0.4%
5.2%
6
Nature Communications
based on 483 papers
Top 17%
4.6%
7
Clinical Immunology
based on 12 papers
Top 0.2%
4.4%
8
Science Immunology
based on 15 papers
Top 0.1%
4.4%
9
Annals of the Rheumatic Diseases
based on 23 papers
Top 0.6%
4.4%
10
Clinical Infectious Diseases
based on 219 papers
Top 7%
3.8%
50% of probability mass above
11
Frontiers in Immunology
based on 140 papers
Top 3%
2.8%
12
Journal of Clinical Investigation
based on 50 papers
Top 0.8%
2.8%
13
Nature Medicine
based on 88 papers
Top 3%
2.8%
14
JCI Insight
based on 63 papers
Top 3%
2.5%
15
PLOS ONE
based on 1737 papers
Top 84%
2.4%
16
Cell Reports Medicine
based on 49 papers
Top 2%
2.4%
17
Cell
based on 28 papers
Top 1%
2.3%
18
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 1.0%
1.6%
19
Genome Medicine
based on 56 papers
Top 5%
1.6%
20
Journal for ImmunoTherapy of Cancer
based on 14 papers
Top 2%
1.3%
21
eLife
based on 262 papers
Top 23%
1.3%
22
Communications Biology
based on 36 papers
Top 3%
1.3%
23
The American Journal of Human Genetics
based on 77 papers
Top 6%
1.3%
24
Blood
based on 14 papers
Top 0.8%
1.2%
25
Immunity
based on 11 papers
Top 0.8%
1.2%
26
npj Vaccines
based on 18 papers
Top 0.8%
0.8%
27
Science Translational Medicine
based on 40 papers
Top 5%
0.8%
28
mSphere
based on 27 papers
Top 2%
0.8%
29
Journal of Medical Virology
based on 95 papers
Top 11%
0.7%
30
EBioMedicine
based on 21 papers
Top 3%
0.7%